TELO Stock Risk & Deep Value Analysis
Telomir Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About TELO Stock
We analyzed Telomir Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TELO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TELO Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is the failure of TLM-201 in clinical trials or the inability to secure further funding. Without revenue, the company is entirely dependent on its drug candidate's success and continuous capital infusions, which could lead to severe dilution or even bankruptcy if funding or trial results disappoint.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
No revenue generation and consistent net losses since inception.
- ⚠
Significant cash burn requiring dilutive capital raises.
- ⚠
Extremely high Price-to-Book (94.48) and Price-to-Tangible Book Value (100.62) for a pre-revenue company.
- ⚠
No major strategic partnerships secured despite early-stage drug development.
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for TLM-201
- 📅
Inability to secure further financing without significant dilution
- 📅
Increased cash burn exceeding expectations
When to Reconsider
- 🚪
Negative or significantly delayed clinical trial results for TLM-201.
- 🚪
Announcement of substantial new share dilution without a corresponding major partnership or clinical breakthrough.
- 🚪
Accelerated increase in cash burn rate without clear justification or new funding.
Unlock TELO Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Telomir Pharmaceuticals Inc (TELO) Do?
Market Cap
$45.38M
Sector
Healthcare
Industry
Biotechnology
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Visit Telomir Pharmaceuticals Inc WebsiteInvestment Thesis
Telomir Pharmaceuticals represents a highly speculative, high-reward investment opportunity banking on the transformative potential of TLM-201 in age-related diseases and cancer. If successful in clinical trials, the drug could address vast markets, justifying the significant analyst-implied upside. This is a pure binary bet on clinical success and future partnerships.
Is TELO Stock Undervalued?
Unlock the full AI analysis for TELO
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TELO Price Targets & Strategy
12-Month Target
$15.00
Bull Case
$25.00
Bear Case
$0.50
Valuation Basis
Based on analyst consensus median price target, reflecting highly speculative future clinical success of TLM-201 and potential market penetration, rather than current fundamental metrics.
Entry Strategy
Given extreme volatility and high risk, a highly speculative entry near current price levels ($1.00-$1.50) could be considered only by high-risk tolerant investors; no clear technical support levels are available in provided data.
Exit Strategy
Take profit at analyst targets ($15.00-$20.00) if significant clinical milestones are met; implement a strict stop-loss at $0.75 if no progress or adverse events occur.
Portfolio Allocation
Maximum 0.5-1% for highly aggressive, speculative portfolios only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is TELO Financially Healthy?
Balance Sheet
Current Ratio
5.14
Debt/Equity
0.08
Total Debt
$93,432
Cash & Equivalents
$754,323
Cash Flow
Operating Cash Flow
-$3.17M
Does TELO Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable
Moat Sources
1 Identified
The durability of Telomir's 'moat' (IP) is entirely dependent on the successful clinical development and regulatory approval of TLM-201. Without commercialization, the IP offers potential but no current market advantage.
Moat Erosion Risks
- •Clinical trial failure or unexpected adverse events for TLM-201.
- •Challenges to the validity or breadth of TLM-201's patents.
- •Emergence of superior or more advanced telomerase inhibition therapies from competitors.
TELO Competitive Moat Analysis
Sign up to see competitive advantages
TELO Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data provided, but generally speculative for early-stage biotechs)
Institutional Sentiment
Positive (Analyst consensus 'Moderate Buy' with high price targets, implying belief in future success)
Insider Activity (Form 4)
No specific Form 4 filings or insider transactions reported in last 90 days.
Options Flow
Normal options activity (No specific unusual activity reported in provided data).
Earnings Intelligence
Next Earnings
2026-05-13
Surprise Probability
Medium
Historical Earnings Pattern
Tends to miss EPS estimates for early-stage, pre-revenue operations (Q2 2025 EPS -$0.17 missed estimate by $0.09). Price reaction is likely driven by any clinical or partnership news rather than financial results.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (No specific direct competitors in telomerase inhibition are provided in the market intelligence)
Market Share Trend
Not applicable; pre-commercialization.
Valuation vs Peers
Cannot be directly compared on traditional metrics (P/E, P/S) due to lack of revenue/profit. Its high P/B is typical for speculative biotech with significant IP/R&D in early stages.
Competitive Advantages
- •Proprietary drug candidate (TLM-201) and associated intellectual property.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive TELO Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated May 13, 2026)
Medium-Term (6-18 months)
- •Phase 1 clinical trial data readout for TLM-201 (timing uncertain)
- •Potential strategic partnership for TLM-201 development/commercialization
Long-Term (18+ months)
- •Successful progression of TLM-201 through later-stage clinical trials
- •Regulatory approval and market launch of TLM-201 for initial indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TELO?
- ✓
Any formal announcements regarding TLM-201 clinical trial progress (e.g., Phase 1 completion, initiation of next phase).
- ✓
Securing a major strategic partnership with a larger pharmaceutical company.
- ✓
Significant changes in cash runway or burn rate.
Bull Case Analysis
See what could go right with Premium
Competing with TELO
See how Telomir Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Telomir Pharmaceuticals Inc TELO | $45.4M | 2.8 | — | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Telomir Pharmaceuticals Inc (TELO)?
As of March 25, 2026, Telomir Pharmaceuticals Inc has a DVR Score of 2.8 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Telomir Pharmaceuticals Inc?
Telomir Pharmaceuticals Inc's market capitalization is approximately $45.4M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Telomir Pharmaceuticals Inc use?
TELO is the ticker symbol for Telomir Pharmaceuticals Inc. The company trades on the NCM.
What is the risk level for TELO stock?
Our analysis rates Telomir Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Telomir Pharmaceuticals Inc's revenue growing?
Telomir Pharmaceuticals Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is TELO stock profitable?
Telomir Pharmaceuticals Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the TELO DVR analysis updated?
Our AI-powered analysis of Telomir Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 25, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TELO (Telomir Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.